Primary Peptides
Developer of peptide-based therapeutics for neurological disorders. The company focuses on three platform approaches — peptide-mediated protein-protein interaction blockade, peptide-directed targeted protein degradation routed to lysosome or proteasome, and peptide molecular glues — with assets targeting acute stroke, Parkinson’s disease (α-synuclein) and ALS/FTD (TDP-43). The platform combines proteome informatics and computational discovery with in vitro and in vivo validation and has advanced at least one asset through Phase 1 clinical testing.
Industries
Nr. of Employees
small (1-50)
Primary Peptides
Vancouver, Alberta, Canada, North America
Products
K13
Neuroprotective therapeutic peptide targeting PTEN and NEDD4 pathways for acute ischemic and hemorrhagic stroke; reported positive Phase 1 safety and PK data and proposed for Phase 2 testing.
K13V (stroke-triggered gene vector)
Preclinical stroke‑triggered gene vector designed to express the K13 peptide upon stroke occurrence to mitigate brain damage in at‑risk individuals or those with vascular dementia.
PP-003
Preclinical peptide degrader targeting α‑synuclein for Parkinson’s disease; reported to reduce α‑synuclein levels, reduce aggregation and brain inflammation, and rescue behavioral deficits in multiple models.
PP-007
Preclinical interference peptide targeting TDP‑43 phosphorylation (CK‑1δ axis) intended for ALS and frontotemporal dementia; reported to block phosphorylation and aggregation, reduce neuronal cell death and spinal cord inflammation in models.
CHAPTAC
A proprietary targeted protein degradation platform technology that reversibly degrades disease-causing proteins via lysosomal or proteasomal degradation machineries using cell-permeable targeting peptides.
Chaperone-Mediated Autophagy Protein Degradation Technology (CHAPTAC)
A proprietary protein degradation platform technology that reversibly degrades disease-causing proteins via the lysosome or the proteasome degradation machineries of the cell using cell-permeable targeting peptides.
K13
Neuroprotective therapeutic peptide targeting PTEN and NEDD4 pathways for acute ischemic and hemorrhagic stroke; reported positive Phase 1 safety and PK data and proposed for Phase 2 testing.
K13V (stroke-triggered gene vector)
Preclinical stroke‑triggered gene vector designed to express the K13 peptide upon stroke occurrence to mitigate brain damage in at‑risk individuals or those with vascular dementia.
PP-003
Preclinical peptide degrader targeting α‑synuclein for Parkinson’s disease; reported to reduce α‑synuclein levels, reduce aggregation and brain inflammation, and rescue behavioral deficits in multiple models.
PP-007
Preclinical interference peptide targeting TDP‑43 phosphorylation (CK‑1δ axis) intended for ALS and frontotemporal dementia; reported to block phosphorylation and aggregation, reduce neuronal cell death and spinal cord inflammation in models.
CHAPTAC
A proprietary targeted protein degradation platform technology that reversibly degrades disease-causing proteins via lysosomal or proteasomal degradation machineries using cell-permeable targeting peptides.
Chaperone-Mediated Autophagy Protein Degradation Technology (CHAPTAC)
A proprietary protein degradation platform technology that reversibly degrades disease-causing proteins via the lysosome or the proteasome degradation machineries of the cell using cell-permeable targeting peptides.
Expertise Areas
- Peptide therapeutics
- Protein-protein interaction inhibition
- Targeted protein degradation
- Neurology / neuroscience research
Key Technologies
- Peptide therapeutics
- Chaperone-mediated autophagy and proteasomal routing for targeted degradation
- Peptide-based molecular glues
- Cell-penetrating peptide domains and BBB-penetrant peptides
News & Updates
Corporate and pipeline overview; development status of K13, K13V, PP-003 and PP-007; fundraising and milestone plan.
Publication describing peptide-directed lysosomal degradation (CHAPTAC platform) and reversible knockdown of endogenous proteins.
Preclinical study reporting development and efficacy of an α‑synuclein knockdown peptide in PD models.
Publication linking PTEN nuclear translocation with neuronal injury; cited in company pipeline rationale.
Preclinical study referenced in pipeline materials related to signaling pathways and targets.
Reported positive Phase 1 safety and pharmacokinetic data for a neuroprotective peptide intended for acute stroke.
Corporate and pipeline overview; development status of K13, K13V, PP-003 and PP-007; fundraising and milestone plan.
Publication describing peptide-directed lysosomal degradation (CHAPTAC platform) and reversible knockdown of endogenous proteins.
Preclinical study reporting development and efficacy of an α‑synuclein knockdown peptide in PD models.
Publication linking PTEN nuclear translocation with neuronal injury; cited in company pipeline rationale.
Preclinical study referenced in pipeline materials related to signaling pathways and targets.
Reported positive Phase 1 safety and pharmacokinetic data for a neuroprotective peptide intended for acute stroke.